NUVL – nuvalent, inc. - class a (US:NASDAQ)
Stock Stats
News
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 [Yahoo! Finance]
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally [Yahoo! Finance]
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration [Yahoo! Finance]
Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Form 144 Nuvalent, Inc. Filed by: Balcom Alexandra
Form 3 Nuvalent, Inc. For: Mar 16 Filed by: Lane Benjamin
Form 4 Nuvalent, Inc. For: Mar 12 Filed by: Pelish Henry E.
Form 144 Nuvalent, Inc. Filed by: Pelish Henry E.
Form 4 Nuvalent, Inc. For: Mar 06 Filed by: Porter James Richard
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.